North China Pharmaceutical's "National Centralized Procurement Out of Stock" was included in the "List of Violations"

On August 20, Shanghai Sunshine Pharmaceutical Purchasing Network issued a "Announcement on Including North China Pharmaceutical Co.

Suspension of supply to Shandong, ban on declaration for 9 months

According to the announcement, North China Pharmaceutical Co.

Therefore, in accordance with the relevant provisions of the third batch of national centralized procurement "National Drug Centralized Procurement Document (GY-YD2020-1)", after collective deliberation by the member units of the Joint Drug Procurement Office of the State Organization, it was decided to include Huabei Pharmaceutical on the "List of Violations.

On the day before the announcement (August 19), the Shandong Provincial Public Resources Trading Center issued an announcement stating that Zhuhai Rundu Pharmaceutical Co.

Centralized drug supply cuts occur from time to time, and North China Pharmaceutical is not the first

A reporter from Medical Valley checked previous relevant reports.

On April 14 this year, the Zhejiang Pharmaceutical Equipment Procurement Center issued the "Notice on Announcement of the Results of Cefmetazole Injection with Volume Procurement".

In order to strengthen the management of enterprises participating in centralized procurement of drugs and medical consumables, Article 58 of the "Medical Security Law (Draft for Comment)" issued by the National Medical Security Administration on June 16, 2021 stipulates: "Pharmaceutical companies have one of the following circumstances The medical security administrative department shall order corrections and confiscate the illegal income; if the bid is won, the bid won shall be invalid, and a fine of 5‰ to 10‰ of the amount of the bid shall be imposed; the legal representative, the main person in charge, the directly responsible person in charge and other responsibilities shall be imposed The personnel shall impose a fine of 5% to 10% of the unit’s fine; if the circumstances are serious, the qualification of relevant pharmaceutical companies or relevant drugs and medical consumables to participate in centralized procurement shall be restricted or suspended and an announcement shall be made; if other laws and administrative regulations are violated, the relevant The competent department shall impose penalties according to law:

(1) Bidding at a price lower than the cost, or bidding through fraud, bid collusion, abuse of market dominance, etc.

(2) Offering bribes to medical security agencies, centralized procurement agencies, designated medical institutions and their staff;

(3) After winning the bid, waive the qualification for selection without proper reason, fail to sign the purchase and sale agreement in time, fail to fulfill the supply promise, fail to supply the goods in accordance with the agreement and relevant laws and regulations;

(4) Other illegal acts in the bidding process

Won the bid with the highest price, the cost issue may be the reason for the abandonment of the bid

Ibuprofen sustained-release capsules are suitable for alleviating mild to moderate pain such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, dysmenorrhea; also used for fever caused by common cold or influenza

On August 20, 2020, the third batch of nationally collected varieties officially opened bids, and nearly 200 pharmaceutical companies participated in the bidding

According to the relevant regulations in the third batch of national drug centralized procurement documents, if the actual number of selected companies in the country is 4 or more, the current round of procurement cycle is in principle 3 years, and the procurement agreement is signed every year during the procurement cycle

It is understood that Shandong Province officially implemented the third batch of national procurement results on November 16, 2020.

Why is there a shortage of supply?

North China Pharmaceutical is the first large pharmaceutical factory in the founding of the People’s Republic of China.

According to a person from a pharmaceutical company told a reporter from China Business News, that the drug company’s stock out of centralized procurement may be due to various reasons, such as insufficient supply of raw materials, and the company’s original sales market for the drug is limited.

According to Wang Hongzhi, general manager of the medical industry center of Peking University's Zongheng Management Consulting Company, "In fact, this incident can give all companies a warning.

As of press time, North China Pharmaceutical has not given an official explanation for this, and Yigu will continue to pay attention to the progress of the incident